Delving into the Latest Updates on Amlodipine orotate/Valsartan with Synapse

Overview

Basic Info

Drug Type

Small molecule drug

Synonyms

Orosartan

Target

AT1R x VDCCs

Action

antagonists, blockers

Mechanism

AT1R antagonists(Angiotensin II Receptor Type 1 antagonists), VDCCs blockers(Voltage-gated calcium channel blockers)

Therapeutic Areas

Cardiovascular Diseases

Active Indication

Hypertension

Inactive Indication-

Originator Organization

Dong-A Pharmaceutical Co., Ltd.

Active Organization

Dong-A Pharmaceutical Co., Ltd.

Inactive Organization-

Drug Highest PhaseApproved

First Approval Date

South Korea (01 Jan 2013),

Hypertension

Regulation-

Login to view timeline

Structure/Sequence

Molecular FormulaC25H29ClN4O9

InChIKeyDBGOBQCYSPDGNR-UHFFFAOYSA-N

CAS Registry914941-70-1

View All Structures (2)

Hypertensive patients with moderate hypertension have a risk to develop cardiovascular events of 15-20% over a period of 10 years. It is important to reach quickly the advised target, but often this result can be obtained with a combination therapy. Some evidences demonstrate sartans and calcium channels blockers can be very useful and safe, but it is also important to verify which association can give side effects or give some pharmacokinetic interactions that can negatively influence the clinical combination efficacy.

Start Date01 Jul 2008

Sponsor / Collaborator

Universitiamo By Unipv

100 Clinical Results associated with Amlodipine orotate/Valsartan

Login to view more data

100 Translational Medicine associated with Amlodipine orotate/Valsartan

Login to view more data

100 Patents (Medical) associated with Amlodipine orotate/Valsartan

Login to view more data

3

Literatures (Medical) associated with Amlodipine orotate/Valsartan

01 Dec 2004·Journal of Dermatological ScienceQ2 · MEDICINE

Cutaneous mixed tumors: an immunohistochemical study using two antibodies, G-81 and C8/144B

Q2 · MEDICINE

Letter

Author: Kazunori Sagawa ; Tsutomu Tsuji ; Fukumi Furukawa ; Koji Uede ; Yoshimi Minami ; Akihiko Kimura

A review.The expression and localization of dermcidin (DCD) and cytokeratin 15 (K15) were investigated in 26 cases of cutaneous mixed tumors (CMTs) to elucidate more detailed information about the histogenesis of these tumors.The primary antibodies used for immunostaining included the mouse anti-human monoclonal antibody of clone G-81 and the DAKO clone C8/144B.Thirteen out of the 26 CMTs were G-81 immunopos. in the inner cells of localized, comparatively small tubular structures, similar to that seen in the secretory cells of eccrine sweat glands.Pos. immunostaining for C8/144B was defined by the presence of granular cytoplasmic immunostaining of the outer cells of the tubular structures in various tumor cells in the solid nests.Both G-81 and C8/144B were immunopos. in four cases, but these reactions were recognized in different areas.Nine cases were immunopos. only for G-81 and eight cases were immunopos. only for C8/144B.

01 Jul 2004·British Journal of DermatologyQ1 · MEDICINE

Immunohistochemical staining of cutaneous tumours with G-81, a monoclonal antibody to dermcidin

Q1 · MEDICINE

Article

Author: A. Kimura ; K. Uede ; Y. Minami ; T. Tsuji ; F. Furukawa ; K. Sagawa

BACKGROUNDRecently, the novel antimicrobial peptide named dermcidin (DCD) was reported in human eccrine sweat glands.OBJECTIVESWe investigated the expression of DCD in a variety of cutaneous tumours in order to assess the usefulness of the monoclonal antibody (G-81), which recognizes a fragment of DCD.PATIENTS/METHODSWe studied the immunoreactivity of the G-81 antibody on 197 cutaneous tumours.RESULTSA total of 13 of 26 cutaneous mixed tumours showed substantial immunoreactivity. In contrast all the following cases were completely unreactive: (i) epithelial tumours (seborrhoeic keratosis, squamous cell carcinoma, Bowen's disease, actinic keratosis, genital Paget's disease); (ii) follicular tumours (basal cell carcinoma, trichilemmoma, trichoepithelioma, trichoblastoma, keratoacanthoma, proliferating trichilemmal tumour, pilomatricoma); (iii) melanocytic tumours (malignant melanoma, naevus cell naevus, Spitz naevus, blue naevus); (iv) neural tumours (schwannoma, neurofibroma, Merkel cell neoplasm); (v) mesenchymal tumours (soft fibroma, dermatofibroma, dermatofibrosarcoma protuberans, vascular leiomyoma, leiomyosarcoma, lipoma, juvenile xanthogranuloma, angiomyoma); and (vi) other sweat gland tumours (poroid neoplasms, syringoma, cylindroma, clear cell hidradenoma, spiradenoma, syringoid eccrine carcinoma, mucinous carcinoma, apocrine cystadenoma, syringocystadenoma papilliferum, apocrine adenocarcinoma). Twenty-six cutaneous mixed tumours were considered from histopathological findings to be the apocrine type, but 13 of 26 mixed tumours contained some DCD-immunopositive cells that possibly differentiate into eccrine secretory glands.CONCLUSIONSWe found the expression of DCD in tubular structures of 50% of cutaneous mixed tumours with apocrine differentiation. These results suggest that a number of cutaneous mixed tumours show both eccrine and apocrine differentiation in the same neoplasm.

01 Apr 2003·International Journal of Legal MedicineQ2 · MEDICINE

Production and characterization of a monoclonal antibody for sweat-specific protein and its application for sweat identification

Q2 · MEDICINE

Article

Author: Kazunori Sagawa ; Mizuho Nosaka ; Tsutomu Tsuji ; Hiroshi Inoue ; Seiji Yasuda ; Akihiko Kimura ; Yoshifumi Saito

Identification of body fluids is a common task in medico-legal practice, but specific markers for sweat have not been identified to date. To develop a method for identification of sweat, we identified a sweat-specific protein and produced monoclonal antibodies by immunizing mice with sweat proteins fractionated by anion-exchange chromatography. Among many sweat-reactive monoclonal antibodies obtained, one monoclonal antibody (G-81) was selected because of its unique specificity. G-81 reacted to sweat but not to other body fluids (e.g. serum, saliva, semen, milk, urine and tears) in ELISA. G-81 specifically stained the eccrine sweat gland and did not stain any other tissue including the apocrine sweat gland. In western blotting, G-81 reacted strongly to a 7 kDa band and faintly to 20, 27 and 33 kDa bands of sweat protein. The N-terminal amino acid sequence (18 amino acids) of G-81-reactive peptides was determined, and an identical sequence was found in an antibiotic peptide dermcidin (110 amino acids) reported recently, suggesting that G-81 recognized a fragment of dermcidin. The G-81-reactive peptide could be detected in 8,192-fold dilutions of sweat by ELISA and could be detected in 200-fold diluted sweat samples ( n=26) independent of the protein concentration. The G-81-reactive peptide was very stable and was able to detect sweat stains left for at least 11 weeks at room temperature without substantial loss of reactivity. These facts suggest that G-81 is a very useful tool for sweat identification in medico-legal practice.

100 Deals associated with Amlodipine orotate/Valsartan

Login to view more data